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Abstract
Background: MicroRNAs (miRNAs) are key components of the gene regulatory network in many species. During
the past few years, these regulatory elements have been shown to be involved in an increasing number and range
of diseases. Consequently, the compilation of a comprehensive map of natural variability in a healthy population
seems an obvious requirement for future research on miRNA-related pathologies.
Methods: Data on 14 populations from the 1000 Genomes Project were analyzed, along with new data extracted
from 60 exomes of healthy individuals from a population from southern Spain, sequenced in the context of the
Medical Genome Project, to derive an accurate map of miRNA variability.
Results: Despite the common belief that miRNAs are highly conserved elements, analysis of the sequences of the
1,152 individuals indicated that the observed level of variability is double what was expected. A total of 527
variants were found. Among these, 45 variants affected the recognition region of the corresponding miRNA and
were found in 43 different miRNAs, 26 of which are known to be involved in 57 diseases. Different parts of the
mature structure of the miRNA were affected to different degrees by variants, which suggests the existence of a
selective pressure related to the relative functional impact of the change. Moreover, 41 variants showed a
significant deviation from the Hardy-Weinberg equilibrium, which supports the existence of a selective process
against some alleles. The average number of variants per individual in miRNAs was 28.
Conclusions: Despite an expectation that miRNAs would be highly conserved genomic elements, our study
reports a level of variability comparable to that observed for coding genes.
Background
Among the non-coding RNA elements, microRNAs
(miRNAs) constitute a class of relevant functional and
regulatory factors. miRNAs are short non-coding RNAs
approximately 22 nucleotides long that play an important
role as post-transcriptional regulators [1]. These trans-
acting factors regulate mRNA functionality by modulat-
ing both mRNA stability and the translation of mRNA
into protein [2,3]. Some estimates suggest that a relatively
large amount of the genes in the human genome (which
might comprise up to the 4%) could effectively code for
miRNAs. Such regulatory elements present a broad range
of targets: it is believed that a single miRNA can regulate
the expression of as many as 200 genes [4]. Numerous
studies have involved miRNAs in a large number of key
biological processes, such as cell growth, proliferation,
differentiation, development, and so on [5-7]. As an
obvious consequence of this, miRNA deregulation has
been associated with a large number of diseases, includ-
ing cancers, psychiatric and neurological diseases, and so
on [8]. As in other functionally relevant elements, and
especially due to their crucial regulatory role based on
base complementarity, few mutations are expected to
occur in miRNAs. Actually, most mutations of the
miRNA sequence are expected to have adverse effects on
their functionality or biogenesis [9]. Early studies on
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variability of miRNAs using SNPs reported a very low
level of variation in their functional regions [10]. The
absence of polymorphisms in more than 90% of human
pre-miRNAs has been reported. Moreover, most of the
observed polymorphisms occurred outside the seed
region, suggesting the existence of a strong selective con-
straint on human pre-miRNAs [10]. Even common var-
iants located in miRNAs seem to have effects on
susceptibility to diseases such as cancer [11,12], ulcera-
tive colitis [13] and many others [8]. SNP genotype data
were also used to study the variability at miRNA binding
sites. Different authors have also reported a significantly
low variation at these sites, thus providing independent
support for the notion of high conservation of the
miRNA regulatory network [10,14].
The recent publication of the 1000 Genomes Project has
revealed an enormous amount of variation at the genome
level [15]. An interesting aspect that can be studied from a
population perspective is the occurrence of variations
across the different genomic features. In particular, var-
iants predicted to severely affect the function of human
protein-coding genes, known as loss-of-function (LOF)
variants, have attracted the attention of many researchers
[15]. Such variants are thought to have a potential deleter-
ious effect and have traditionally been associated with
severe Mendelian diseases. However, recent genome
sequencing projects have revealed an unexpectedly large
number of these variants in the genomes of apparently
healthy individuals. A conservative estimate suggests that
there are at least 250 LOF variants per sequenced genome,
100 of them involved in known human diseases, and more
than 30 in a homozygous state, which suggests a pre-
viously unnoticed level of variation with putative func-
tional consequences in protein coding regions in humans
[16].
Therefore, it seems urgent to produce a comprehensive
catalogue of the natural variation of miRNAs in order to
discriminate between pathogenic and non-pathogenic
variants in further studies. It is important to check
whether a restrictive scenario for the existence of varia-
tion is confirmed or, on the contrary, a scenario of varia-
tion similar to that observed with coding genes also
occurs in miRNAs. In order to distinguish between these
two possibilities, we have analyzed the miRNA sequences
of 1,152 individuals to survey the actual levels of variabil-
ity at these genomic elements. The samples belong to 14
populations distributed worldwide, completed with
sequencing data corresponding to 60 exomes from the
Medical Genome Project [17]. Our analysis discovered a
significant number of variants, 527, affecting not only the
pre-processed miRNA but also the mature miRNAs. Still,
a considerable number of these variants (over 35%) have
not yet been reported in dbSNP [18]. The variants found
affect different miRNAs known to be involved in 57
diseases. Actually, 41 variants showed a significant devia-
tion from the Hardy-Weinberg equilibrium (HWE), sug-
gesting that selective pressure might be acting against
them.
Materials and methods
miRNA data sources
miRNAs and their chromosomal coordinates were
obtained from miRBase [4] release 18. The regions within
miRNAs were defined as in Figure 1 (bottom). The seed
region comprising nucleotides 2 to 8 in Figure 1 is a
well-known feature of miRNAs [19,20], although recent
work extends the region to nucleotide 1 [21]. The defini-
tion of the miRNA duplex, including the rest of the ele-
ments (pre-mir and the rest of the miR 5’ and 3’ as well
as the loop) was also taken from the literature [22,23].
The associations of miRNAs to diseases were taken from
the PhenomiR database [24].
Human populations
Fourteen human populations were used in this study: the
European populations TSI (from Toscani in Italia; 98 sam-
ples), FIN (Finnish from Finland; 93 samples), GBR (British
from England and Scotland; 89 samples), CEU (Utah resi-
dents (CEPH collection) with Northern and Western
European ancestry; 85 samples) and IBS (Iberian popula-
tions in Spain; 14 samples); the Asian populations CHB
(Han Chinese in Beijing, China; 97 samples), CHS (Han
Chinese South; 100 samples) and JPT (Japanese in Toyko,
Japan; 89 samples); the American populations MXL (Mexi-
can Ancestry in Los Angeles, CA; 66 samples), PUR
(Puerto Rican in Puerto Rico; 55 samples) and CLM
(Colombian in Medellin, Colombia; 60 samples); and the
African populations YRI (Yoruba in Ibadan, Nigeria; 88
samples), LWK (Luhya in Webuye, Kenya; 97 samples) and
ASW (African Ancestry in Southwest USA; 61 samples).
This selection has been completed with AND, an Andalu-
sian (south of Spain) population composed of 60 samples
from healthy individuals, sequenced in the context of the
Medical Genome Project [17], which can be considered as
equivalent to IBS. AND data have been deposited at the
European Genome-phenome Archive [25], which is hosted
by the European Bioinformatics Institute, under accession
number EGAS00001000324. All these populations together
comprise a total of 1,152 individuals.
Human subjects
The whole genome sequences of the human populations
described above (except AND) were downloaded from
the 1000 Genomes Project web page [26] in multi-sample
VCF format (October 2011 release). Variants in positions
located in the miRNAs were collected for this study.
Following informed consent, the 60 AND samples
were obtained and further anonymized and sequenced.
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Samples were obtained in accordance with the approved
protocols of the respective institutional review boards
for the protection of human subjects. The study con-
formed to the tenets of the declaration of Helsinki.
Construction of DNA libraries and sequencing
Library preparation and Exome capture were performed
according to protocol version 2.1 from Baylor College of
Medicine [27]. Briefly, 5 μg of input genomic DNA was
sheared, end-repaired and ligated with SOLID-specific
adaptors. A fragment size distribution ranging from 160 to
180 bp after shearing and 200 to 250 bp after adaptor
ligation was verified by Bioanalyzer (Agilent, Santa Clara,
California, USA). The library was amplified by pre-capture
LM-PCR (linker mediated-PCR) using the FastStart High
Fidelity PCR System (Roche, Basel, Switzerland). After
purification, 2 μg of the LM-PCR product was hybridized
to NimbleGen SeqCap EZ Exome libraries. After washing,
amplification was performed by post-capture LM-PCR
using the FastStart High Fidelity PCR System (Roche).
Capture enrichment was measured by quantitative PCR
according to the NimbleGen protocol.
The successfully captured DNA was measured by
Quant-iT™ PicoGreen® dsDNA reagent (Invitrogen,
Carlsbad, California, USA) and subjected to standard
sample preparation procedures for sequencing with the
SOLID 4 platform as recommended by the manufacturer.
Briefly, emulsion PCR was performed on the E20 scale
(about 250 million template beads) using a concentration
of 0.343 pM of enriched captured DNA. After breaking
and enrichment, about 128 million enriched template
beads were sequenced per well on a four-well SOLID
slide.
Analysis of sequencing data
The analysis was done using the pipeline of the Medical
Genome Project. Briefly, sequence reads were aligned to
the reference human genome build GRCh37 (hg19) by
using the Burrows-Wheeler alignment (BFAST tool) [28].
Properly mapped reads were filtered with SAMtools [29],
which was also used for sorting and indexing mapping files.
Only high quality sequence reads with unique mapping
positions to the reference human genome were used for
calling variants. Identification of variants in the alignment
Figure 1 Structure of a pre-miRNA, an miRNA precursor. Top: distribution of all the variants observed in all the populations analyzed across
the different substructures of the pre-miRNA. Bottom: the theoretical pre-miRNA. The mature miRNA is composed of the seed miR 5’ and the
rest of miR 5’ (and the other mature miRNA is the same for the 3’).
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files was performed using the Genome Analysis Toolkit
[30]. Known SNPs were obtained from the National Center
for Biotechnology Information dbSNP build 135 [31] and
the 1000 Genomes Project [26] (October 2011 release).
Characterization of variants across samples was per-
formed by custom applications developed in Java. Each var-
iant profile summarized zygosity, mean coverage, and
mean alternative allele frequency across samples. The
miRNA identifier and corresponding pre-mir substructure
for each variant were obtained by matching variant loca-
tion with pre-mir coordinates retrieved from miRBase [32].
miRNA variant analysis was performed by custom R [33]
scripts. Computed features from analysis were: single
nucleotide variant (SNV) frequency (per pre-mir and
mature miRNA, per pre-mir substructure, and per sub-
ject), subject frequency (per variant and per pre-mir and
mature miRNA), disease frequency (per pre-mir), and pre-
mir frequency (per subject and disease).
Deviations from the Hardy-Weinberg proportions were
tested with a c2 test [34] as evidence for possible selection
against the alternative allele homozygote. Principal com-
ponent analysis was carried out using the Eigenstrat pro-
gram [35]. Hive plots were obtained using the R package
HiveR [36]. All clustering charts were created using the
Heatmap command of R stats package [33].
Validation of selected variants in miRNA genes by
PCR-based direct genomic sequencing
Peripheral blood samples were collected from all subjects
for genomic DNA purification using an automated DNA
extractor (MagNA Pure LC Instrument, Roche Diagnos-
tics, Basel, Switzerland). In order to validate the variations
detected by next-generation sequencing, specific primers
were designed using the Primer 3 Output program [37].
PCR conditions and primer sequences employed are avail-
able upon request. The amplified products were subse-
quently purified using an enzymatic procedure, according
to the manufacturer’s recommendations (EXOSAP-IT®,
USB Corporation, Cleveland, Ohio, USA) and sequenced
with a ready reaction kit (BigDye Terminator Cycle FS
Ready Reaction kit; PE-Applied Biosystems, Foster City,
CA, USA). The fragments obtained were purified using
fine columns (Sephadex G-501, Sigma-Aldrich Co., St.
Louis, Missouri, USA) and resolved on an automated
sequencer (3730 DNA Analyzer, Applied Biosystems,
Carlsbad, California, USA). Finally, the data were analyzed
using Lasergene DNASTAR® software (DNASTAR, Inc.,
Madison, WI, USA).
Results and discussion
Variants found in miRNAs
The capture kit used in the exome enrichment (see Mate-
rials and methods) contains 720 miRNAs. In this study we
have focused on these regions, as representative of the
variability of the whole spectrum of human miRNAs.
In the case of the 14 populations from the 1000 Genomes
Project, the genomic variant files (VCF) were downloaded
from the 1000 Genomes Project web site and mapped
over the genomic positions of the 720 miRNAs. The
variants corresponding to these regulatory elements were
considered for the study. In the case of the newly
sequenced Spanish samples, the sequencing reads were
mapped onto the chromosomal coordinates of miRNAs
and the variants were called as described in Materials and
methods. The average coverage observed in these regions
was satisfactory (approximately 40×) and the frequency of
the alternative allele when the variant call was heterozy-
gous was over 30% of the reads. These results ensured the
quality of the variant calling process.
A total of 527 different sites located within the com-
plete pre-miRNA structures of the 1,152 individuals
analyzed were affected by SNVs. Table 1 summarizes
the SNVs found in this study and Additional file 1 con-
tains a comprehensive description of the variability map
found in human miRNAs. Thirty-five percent of these
SNVs were not present in dbSNP, indicating that mas-
sive sequencing still has considerable potential for var-
iant discovery. Also among these SNVs, 45 affected the
5’ and 3’ seed regions and occurred in 44 different miR-
NAs. Sixty percent of these miRNAs (26) have pre-
viously been linked to diseases, according to the human
miRNA disease databases [8,24]. In the case of the 60
new Spanish individuals sequenced, 11 so far unde-
scribed variants were found (Table 2) among the 92
SNVs detected. Almost all of them were unique variants.
Two of them could not be validated (see Materials and
methods) due to technical problems. Actually, hsa-mir-
1324 validation was inconclusive because multiple bands
appeared in the gel. When this miRNA was checked in
miRBase, we found that it was withdrawn because of
poor structure (entry MI0006655) but it was included
again (entry MI0006657). This entry contains a note of
caution because some additional sequences reported for
this miRNA [38] did not meet miRBase requirements
for miRNA identification. This could explain the diffi-
culties found in its validation.
While previous estimations of variability suggested that
only about 10% of the miRNAs will be affected by poly-
morphisms [10], our study reports 44% have variants in
the analyzed populations. Moreover, 17% contain var-
iants in critical regions of the mature miRNA. Another
possible comparison comes from the 1000 Genomes
Project, which recently reported an unexpected amount
of deleterious mutations in the coding genes of approxi-
mately 250 to 300 of these LOF variants per individual
[15]. Considering 21,160 protein coding genes (accord-
ing to Ensembl, human genome version GRCh37.p5),
there is a ratio of 0.014 LOF variants per gene in the
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genome. If we consider those SNVs located in the seed
regions as potentially functional variants, the equivalent
resulting ratio would be 0.05 functional variants per
miRNA, which is 3.5-fold higher than for protein coding
regions. Despite the simplicity of this comparison, it
reveals a scenario with a level of variability higher than
previously expected.
The distribution of SNVs in the miRNAs across indivi-
duals in different populations is consistent with the known
historical divergences among populations [39,40]. Figure 2
shows a principal component analysis that clearly segre-
gates the four main populations: African, European, Asian
and American. Human population migrations is a well-
known factor in the determination of current patterns of
intra- and inter-population genetic diversity [41]. Figure 3
shows the distribution of SNVs per individual for the dif-
ferent geographical origins, derived from the analyzed
populations. African populations, as expected, display the
highest variability: 37.2 variants per individual mapping
onto miRNAs, versus averages ranging between 24 and 29
in the other geographical origins.
The distribution of variants among the different miR-
NAs is not uniform. While most of them were affected by
only one SNV, 19 mature miRNAs are affected by 2 SNVs,
among which are hsa-miR-302b*, associated with carci-
noma, glioma, embryonal carcinoma and prostatic, thyroid
and skin neoplasms, and hsa-miR-629, associated with
liver, colonic and testicular neoplasms and lymphomas,
according to the Human MicroRNA Disease database [8].
In addition, two mature miRNAs are affected by three
SNVs, hsa-miR-323b-5p and hsa-miR-936, with no known
association to any disease described to date. This observa-
tion indicates that multiple mutations rarely occur in miR-
NAs associated with diseases.
The variants were not homogeneously distributed across
the structure of the pre-miRNA. Figure 1 (top) shows the
distribution of the occurrence of variants along the differ-
ent pre-miRNA substructures. As expected, the regions
corresponding to the mature miRNA as well as the loop
(see Figure 1 (bottom) for the description of the miRNA
regions) displayed a lower occurrence of variants than the
rest of the miR 5’ and 3’ regions. Table 3 contains a com-
prehensive description of all the SNVs located in the seed
regions, putatively critical for the functionality of miRNA,
which occurs by complementarity with their respective
targets. A total of 45 SNVs were found in these critical
regions, which comprise 8% of the total variants found.
Zygosity, allele frequencies and selective pressures
As expected, most of the variants found in the studied
samples were heterozygotes (399 out of 527, approximately
75%). However, for one-fourth of the variants detected
(128) the alternative allele was homozygous in at least one
individual. Also according to the expectations, allele popu-
lation frequencies were low for most SNVs. Figure 4 shows
the distribution of variants according to their allele fre-
quency estimated from the populations used in this study.
A classical way to verify the existence of variants under
negative selection (and, consequently, probably patho-
genicity) is to check for deviations from HWE [34].
Table 1 Summary of variant positions found
Origin Population Subjects SNVs SNVs in
dbSNP
SVNs in
precursor
SVNs in
mature
Number of
heterozygous
Number of
homozygous
miRNA with
disease
Diseases
European IBS 14 78 75 70 15 52 26 21 76
AND 60 92 77 81 21 55 37 30 82
CEU 85 132 119 116 29 87 45 42 102
TSI 98 147 127 120 32 104 43 120 109
GBR 89 131 114 110 28 80 51 43 107
FIN 93 118 103 102 25 72 46 36 95
Asian CHS 100 114 92 93 28 65 49 30 88
CHB 97 123 99 104 25 77 46 30 91
JPT 89 120 108 103 32 72 42 38 96
American MXL 66 132 111 110 34 82 50 38 90
PUR 55 152 141 117 35 107 45 41 85
CLM 60 141 124 114 28 90 51 37 88
African LWK 97 229 187 179 59 158 71 70 104
ASW 61 206 177 158 54 145 60 60 108
YRI 88 207 175 169 53 130 77 169 133
Origin, geographical origin of the population; Population, population code according to the 1000 Genomes Project (see Materials and methods); Subjects,
number of sequenced subjects per population; SNVs, number of SNVs found in the population; SNVs in dbSNP, how many of these variants are already described
in dbSNP; SVNs in precursor, how many of the SNVs map within the miRNA precursor structure (Figure 3, bottom); SVNs in mature, how many of the SNVs map
within the miRNA mature structure (Figure 2, bottom); Number of heterozygous, the number of times that the SNV occurred heterozygously; Number of
homozygous, the number of times that the alternative allele occurred homozygously; miRNA with disease, the number of miRNAs associated with at least one
known disease, with at least one SNV, in the corresponding population; Diseases, the total number of diseases with which the miRNAs are associated.
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Table 2 New variants found in the newly sequenced Spanish population (AND) arranged by chromosome location
Location SNV Pre-mir/mature Region Number of individuals Population frequency (%) Number of heterozygous Number of homozygous Validated
Chr1:236016354 C/G hsa-mir-1537 5’ mir (mix) 1 0.0868 1 0 Yes
Chr 3:10436198 G/A hsa-mir-885/hsa-miR-885-3p 3’ seed miR 1 0.0868 1 0 Yes
Chr 3:75679944 C/T hsa-mir-1324 5’ mir (mix) 2 0.1736 2 0 NCa
Chr 4:8007067 G/A hsa-mir-95 5’ mir (mix) 1 0.0868 1 0 Yes
Chr 9:97847780 C/T hsa-mir-27b Loop 1 0.0868 1 0 Yes
Chr 12:49048256 G/A hsa-mir-1291 3’ mir (mix) 1 0.0868 1 0 Yes
Chr 14:23887249 C/G hsa-mir-208b 5’ mir (mix) 1 0.0868 1 0 NDb
Chr 14:101347358 C/T hsa-mir-431 5’ mir 1 0.0868 1 0 Yes
Chr 14:101506800 G/C hsa-mir-376b 5’ mir (mix) 1 0.0868 1 0 Yes
Chr 14:101513665 A/T hsa-mir-539 5’ mir 1 0.0868 1 0 Yes
Chr 14:101531692 T/C hsa-mir-409/hsa-miR-409-3p 3’ rom miR 1 0.0868 1 0 Yes
Location, the location (chromosome:position, according to the human genome build GRCh37, hg19); SNV, the change observed (reference allele/alternative allele); Pre-mir/mature, the identifier of the pre-mir and
the mature miRNA affected by the SNV; Region, the region in which the SNV maps within the miRNA structure (Figure 3, bottom), with several cases where regions cannot be defined with precision due to a lack
of a detailed annotation (3’ mir (mix) = loop + seed miR 3’ + rest of miR 3’ + 3’ pre-mir; 5’ mir (mix) = loop + seed miR 5’ + rest of miR 5’ + 5’ pre-mir; we also use the abbreviations 5’ rom miR = rest of miR 5’ and
3’ rom miR = rest of miR 3’); Number of individuals, the number of individuals supporting the SNV; Population frequency (%), the alternative allele frequency in the studied population; Number of heterozygous, the
number of times the SNV occurred heterozygously; Number of homozygous, the number of times that the alternative allele occurred homozygously. aNC, non-conclusive results after using two independent pairs of
primers; a double band makes a precise determination of the SNV impossible. bND, not determined because no more DNA was available.
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HWE states that, given a series of assumptions, both
allele and genotype frequencies in a population remain
constant (in equilibrium) with time unless specific dis-
turbing influences are introduced. Deviations from this
equilibrium can be tested with a conventional chi-square
test. Selective pressures against one of the alleles are one
of the most common factors that can produce this devia-
tion. Table 4 shows 41 SNVs belonging to all the popula-
tions analyzed that were significantly deviated from the
HWE. Actually, the real number might be higher because
the small sizes of the populations available for the study
(around or below 100 individuals) preclude the possibility
of obtaining lower P-values even for highly deviated
proportions.
Again, comparisons to the number of LOF variants in
coding genes can be done if SNVs significantly deviated
from HWE are considered as potentially functional. In this
case, the resulting ratio would be 0.08 functional variants
per variant miRNA. This value is 5.5-fold higher than the
ratio of LOF variants observed in protein coding regions.
Diseases associated with miRNAs with variants and
potential consequences
The process of human migrations in the past has played a
key role in determining current patterns of genetic diver-
sity and could partially explain inter-population varia-
tions in genetic susceptibility to certain diseases [41,42].
As previously discussed, variants affecting essential
regions of the miRNAs, such as the seed or the loop,
have a high probability of having consequences on
miRNA functionality. Moreover, it has been described
that variants affecting other regions of the miRNA struc-
ture can also adversely effect its functionality [9]. Given
that miRNAs target many different mRNA sequences,
SNVs affecting them are expected to cause considerable
pleiotropic effects. Moreover, given that the mode of
action of miRNAs implies interference of the mRNAs of
their target genes with consequent inhibition of the cor-
responding gene product, a dominant or codominant
(having incomplete penetrance) effect would be expected
from a variant that affects an miRNA’s functionality.
Additional file 2 lists the diseases in which different miR-
NAs with variants in the studied population have been
reported to be involved, according the PhenomiR human
miRNA disease database [24].
Among the 527 variants found in this work, 45 affected
the recognition region of the corresponding miRNA and
were found in 43 different miRNAs, 26 of which are
known to be involved in 57 diseases. Many of these dis-
eases are cancers, probably because the studies are quite
recent and have been carried out mainly from this per-
spective. However, many miRNAs are involved in other
diseases of different etiologies; the fact that a consider-
able number of them have been associated with more
than one disease highlights the pleiotropic effect of miR-
NAs. This pleitropic effect makes it difficult to under-
stand the relationships between mutations and the
possible effects in cases of miRNAs associated with dis-
eases. Figure 5a shows the similarity between populations
in terms of shared variants at each position of the
miRNA precursor compared. Obviously, intra-population
similarities are higher than inter-population similarities.
Populations from a common geographical region display
higher similarities than when they are compared to popu-
lations of other geographical origins. Overall, the result-
ing clustering obtained for the populations reflects their
historic origins, as expected [41]. However, when only
positions mapping in the seed regions of the miRNA are
considered in the comparison, several populations share
more common SNVs with other populations of different
geographical origins (Figure 5b) than with neighbor
populations. For example, some African, European and
American populations seem to be more similar to each
other than to other populations with closer geographic
origins. This can be explained by the limited repertoire of
mutations that can be tolerated in regions critical for
miRNA functionality. This population intermingling
effect is still more noticeable when the distribution of
diseases across populations is visualized (Figure 5c).
In this case, the effect is a combination of two factors: on
one hand the limited number of miRNAs affected in the
critical regions and, on the other, the pleiotropic effect of
Figure 2 Principal component analysis based on the variability of
the 14 populations from the 1000 Genomes Project and the
Spanish sequenced population. Distances are based on a total of
198 different variant positions in which the sequenced Spanish
population presented a reasonable coverage (>10×) and there was at
least one variant in an individual. Colors are as follows: European
populations in yellow; Asian populations in blue; African populations in
purple and American populations in brown. PC, principal component.
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such miRNAs, which causes a non-proportional distribu-
tion of the diseases. As expected, Africans, due to their
higher variability levels, cover a wider range of potential
diseases. However, the number of diseases is not directly
proportional to the general variability levels of the popu-
lation and depends on the particular repertoire of miR-
NAs affected. The interrelationships between diseases,
populations and miRNAs can be represented by means of
a hive plot. Figure 5d shows such relationships, with the
diseases summarized in general categories. A complex
correspondence between miRNAs and the respective dis-
eases caused is evident. Almost all the miRNAs appear
mutated in almost all the populations and the same can
be said for the diseases. However, Figure 5a shows some
population trends in the diseases, probably due to foun-
der effects.
Putative functional impact
Defective miRNAs cause diseases because of their inabil-
ity to silence the corresponding natural set of target
genes (and eventually by silencing new target genes).
Since miRNAs have multiple targets, it is expected that
they have a collective action over cell functionalities.
Indeed, cases of miRNAs acting on genes involved in par-
ticular functional processes have been described [43-45].
In order to understand the possible impact of the corre-
sponding population mutational load, we have listed the
genes targeted by the 45 different miRNAs with SNVs in
their seed regions and selected the KEGG pathways [46]
containing genes on this list. A total of 34 (of a total of
51) KEGG pathway categories contained genes targeted
by the 45 miRNAs with seed regions affected by SNVs.
Figure 6a shows the distribution of putatively affected
Figure 3 Distribution of the number of variants per individual in the different geographical origins derived from the populations
analyzed. The populations used for the different geographical origins were: EUR (European), including TSI, FIN, GBR, CEU, IBS and AND; ASI
(Asian), including CHB, CHS and JPT); AMR (American) (including MXL, PUR and CLM); and AFR (African), including YRI, LWK and ASW.
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Table 3 SNVs found in all the populations analysed affecting critical regions of miRNAs
Location SNV Pre-mir/mature [dbSNP]/[1000g aaf] Region Number of
samples
Population frequency
(%)
Number of
heterozygous
Number of
homozygous
1:17185500 C/T hsa-mir-3675/hsa-miR-
3675-5p
RS137982850/- 5’ seed miR 1 0.0868 0 1
1:100746814 A/G hsa-mir-553/hsa-miR-553 -/0.00 5’ seed miR 3 0.2604 3 0
1:176998565 T/C hsa-miR-488-5p -/0.00 5’ seed miR 1 0.0868 1 0
3:164059159 G/A hsa-mir-720/hsa-miR-720 -/0.00 5’ seed miR 1 0.0868 1 0
4:113569088 A/G hsa-miR-367-5p RS150161032/0.00 5’ seed miR 1 0.0868 1 0
5:140027435 C/T hsa-mir-3655/hsa-miR-3655 RS146400503/0.01 5’ seed miR 13 1.1285 13 0
7:73605546 C/T hsa-mir-590/hsa-miR-590-
5p
-/0.00 5’ seed miR 4 0.3472 4 0
7:127721934 C/T hsa-miR-593-5p RS73721294/0.02 5’ seed miR 42 3.6458 40 2
10:29891260 C/T hsa-mir-938/hsa-miR-938 RS12416605/0.15 5’ seed miR 301 26.1285 261 40
10:53059349 A/G hsa-mir-605/hsa-miR-605 RS113212828/0.00 5’ seed miR 8 0.6944 8 0
10:105807928 T/C hsa-mir-936/hsa-miR-936 RS79924817/0.01 5’ seed miR 11 0.9549 11 0
13:53384209 C/G hsa-mir-759/hsa-miR-759 RS144233096/0.00 5’ seed miR 4 0.3472 4 0
14:101520657 T/C hsa-miR-382-5p -/0.00 5’ seed miR 1 0.0868 1 0
15:42491848 A/C hsa-mir-627/hsa-miR-627 RS2620381/0.08 5’ seed miR 157 13.6285 145 12
19:46178206 T/G hsa-miR-642a-5p RS78902025/0.00 5’ seed miR 1 0.0868 1 0
1:3477292 C/T hsa-mir-551a/hsa-miR-551a -/0.00 3’ seed miR 10 0.8681 10 0
1:168344829 C/T hsa-mir-557/hsa-miR-557 RS78825966/0.06 3’ seed miR 114 9.8958 98 16
2:176032384 T/C hsa-mir-933/hsa-miR-933 RS139770589/0.00 3’ seed miR 8 0.6944 8 0
3:10436198 G/Aa hsa-mir-885/hsa-miR-885-
3p
New varianta 3’ seed miR 1 0.0868 1 0
3:49311593 G/C hsa-mir-4271/hsa-miR-4271 -/0.00 3’ seed miR 2 0.1736 2 0
3:160122434 G/A hsa-miR-15b-3p -/0.00 3’ seed miR 1 0.0868 1 0
4:1988144 C/A hsa-mir-943/hsa-miR-943 -/0.00 3’ seed miR 2 0.1736 2 0
4:83674520 G/A hsa-mir-575/hsa-miR-575 RS149186367/0.00 3’ seed miR 10 0.8681 10 0
4:117220909 G/A hsa-mir-1973/hsa-miR-1973 -/0.00 3’ seed miR 1 0.0868 1 0
5:54468124 A/T hsa-miR-449c-3p RS35770269/0.25 3’ seed miR 460 39.9306 368 92
5:148810267 C/T hsa-miR-145-3p -/0.00 3’ seed miR 1 0.0868 1 0
5:159912418 C/G hsa-miR-146a-3p RS2910164/0.62 3’ seed miR 933 80.9896 458 475
5:168690635 C/T hsa-mir-585/hsa-miR-585 RS62376935/0.10 3’ seed miR 199 17.2743 176 23
7:150935577 G/A hsa-mir-671/hsa-miR-671-
3p
-/0.00 3’ seed miR 1 0.0868 1 0
8:10682898 A/G hsa-mir-1322/hsa-miR-1322 -/0.00 3’ seed miR 5 0.434 5 0
10:29833959 C/T hsa-mir-604/hsa-miR-604 -/0.00 3’ seed miR 3 0.2604 3 0
12:113132901 G/A hsa-mir-1302-1/hsa-miR-
1302
RS74647838/0.03 3’ seed miR 53 4.6007 50 3
14:101351088 A/C hsa-miR-136-3p RS147448304/0.00 3’ seed miR 1 0.0868 1 0
16:820249 G/A hsa-mir-662/hsa-miR-662 RS9745376/0.05 3’ seed miR 97 8.4201 87 10
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Table 3 SNVs found in all the populations analysed affecting critical regions of miRNAs (Continued)
16:2321809 G/A hsa-mir-940/hsa-miR-940 RS149527765/0.00 3’ seed miR 1 0.0868 1 0
18:56118358 C/T hsa-miR-122-3p RS41292412/0.00 3’ seed miR 10 0.8681 10 0
19:2234080 G/A hsa-mir-1227/hsa-miR-1227 RS139405773/0.00 3’ seed miR 2 0.1736 2 0
19:10662866 G/A hsa-mir-1238/hsa-miR-1238 -/0.00 3’ seed miR 1 0.0868 1 0
19:10928119 A/G hsa-mir-199a-1/hsa-miR-
199a-3p
-/0.01 3’ seed miR 13 1.1285 13 0
19:54200843 C/T hsa-mir-525/hsa-miR-525-
3p
-/0.00 3’ seed miR 1 0.0868 1 0
19:54201692 A/C hsa-miR-523-3p -/0.00 3’ seed miR 3 0.2604 3 0
19:54238189 G/A hsa-mir-518d/hsa-miR-
518d-3p
RS73602910/0.00 3’ seed miR 6 0.5208 6 0
20:33578251 A/G hsa-miR-499a-3p RS3746444/0.18 3’ seed miR 358 31.0764 311 47
20:33578255 C/T hsa-miR-499a-3p RS150018420/0.00 3’ seed miR 3 0.2604 3 0
22:42296995 A/G hsa-miR-33a-3p RS77809319/0.00 3’ seed miR 2 0.1736 2 0
Location, the location (chromosome:position, according to the human genome build GRCh37, hg19); SNV, the change observed (reference allele/alternative allele); Pre-mir/mature, the identifier of the pre-mir and the
mature miRNA affected by the SNV; [dbSNP]/[1000g aaf], the dbSNP identifier and the 1000 Genomes alternative allele frequency; Region, the region in which the SNV maps within the miRNA structure (Figure 1,
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pathways across populations. Despite the large number of
targets affected by the miRNAs, 17 categories are untar-
geted by any miRNA, all of which are related to basic
metabolism, replication, transcription, repair and other
basic cellular functions. Actually, several metabolism
categories (for example, energy metabolism, metabolism
of terpeniods and polyketides, biosynthesis of other sec-
ondary metabolites) are among the less affected cate-
gories across all the populations. On the other side of the
spectrum, pathway categories related to cancer, immune
system, cardiovascular diseases and diverse forms of sig-
naling are among the most affected ones. This observa-
tion is in accordance with the diseases to which the
miRNAs affected have been linked. Again, the patterns of
distribution of diseases for African populations are less
homogeneous than those of other populations. For exam-
ple, in LWK populations pathways of neurodegenerative
diseases and immune system seem to be less affected
than in the other two African populations (YRI and
ASW). There are also some interesting distributions of
patterns. For example, for some populations of different
origins (LKW, GBR and JPT), pathways related to neuro-
degenerative diseases seem to be less affected than other
categories. As in the case of diseases, the relationships
among miRNAs, pathway categories and populations are
complex, as represented in Figure 6b.
Conclusions
An increasing amount of evidence accumulated during
the past few years firmly links miRNAs to numerous
diseases [8,47-49]. Moreover, non-coding RNAs have
been proposed as therapeutic agents given their silen-
cing capabilities [50]. Therefore, detailed knowledge on
natural variation in miRNAs is needed to discriminate
pathological variants from those present in healthy
populations [51,52].
The use of a reasonably large sample of 1,152 indivi-
duals from 15 different populations from 4 geographical
origins allowed us to compile a quite comprehensive cat-
alogue of natural variation in miRNAs. This regulatory
element is expected to be under strong negative selection
and, consequently, highly conserved [10]. However, our
results document an unexpected amount of variability,
comparable (actually higher) to what was recently
described for coding regions [15].
Although it is difficult to properly judge the real role of
this variability, some observations would suggest that,
most likely, a functional impact cannot be ruled out.
Firstly, the occurrence of SNVs across the complete pre-
miRNA structure (Figure 1) is consistent with the relative
importance of the distinct miRNA regions to functional-
ity. Obviously, the seed sequence is crucial for miRNA
functionality, but other regions, such as those next to the
seed, have also recently been involved in miRNA func-
tionality [9]. In the seed regions alone, 45 SNVs disrupt
the recognition site of the miRNA for its targets. In addi-
tion, as expected, heterozygotic variants are more abun-
dant than the alternative allele homozygotic variants
(75.7% versus 24.3%). Moreover, many of the variants
found are low-frequency, rare variants or even variants
specific to individuals. Obviously, approaches based on
rare variants to infer functional impact [53] consider low
frequency as a necessary but not sufficient condition to
justify the existence of a selective pressure against such
variants. On the other hand, selective pressures can also
be inferred by deviations from HWE [34], which occurs
for 41 of these variants.
Although it is impossible to discard the possibility that
any of the healthy controls used in this study will develop
some pathology in the future, it is unlikely that this
occurs for a significant number of them. Therefore, the
apparent neutral effect of potentially deleterious SNVs
found in this study might be either a consequence of a
recessive effect in functionality or due to the fact that
they are neutral changes (despite the fact that they
disrupt regions apparently essential for miRNA
functionality).
It is likely that that many of the variants discovered
that affect essential miRNA regions do have a recessive
effect. Then, the probability of generation of homozygo-
sis by random crossing is non-negligible given the allelic
frequencies. This fact would also suggest that the role of
miRNAs in disease could be stronger than previously
suspected. In any case, the role of such recently discov-
ered variability in shaping the phenotype or in the
occurrence of diseases is still unclear and deserves
further study.
Figure 4 Number of variant positions with different allelic
frequencies. Distribution of SNVs according to their relative allelic
frequencies.
Carbonell et al. Genome Medicine 2012, 4:62
http://genomemedicine.com/content/4/8/62
Page 11 of 17
Table 4 Variant positions with significant deviations from Hardy-Weinberg equilibrium
Population Location Chr:position SNV Pre-mir/mature [dbSNP]/[1000g aaf] Region Number of
subjects
Number of
heterozygous
Number of
homozygous
HWE P-value
AND 5:159912418 C/G hsa-miR-146a-3p RS2910164/0.62 3’ seed miR 35 13 22 2.82 × 10-05
10:135061112 C/T hsa-mir-202 RS12355840/0.71 5’ mir 28 2 26 2.09 × 10-12
X:49767835 A/G hsa-mir-532 RS456617/- 3’ mir 14 4 10 6.87 × 10-09
ASW 2:241395503 T/C hsa-mir-149 RS2292832/0.58 3’ mir 58 35 23 0.044409715
4:1988193 T/C hsa-mir-943 RS1077020/0.26 5’ mir (mix) 32 15 17 0.000302955
14:101522589 C/T hsa-mir-323b/hsa-miR-
323b-5p
RS75330474/0.03 5’ rom miR 3 2 1 0.00016146
15:70371772 C/T hsa-miR-629-5p RS111899904/0.01 5’ rom miR 3 2 1 0.00016146
20:2633466 C/T hsa-mir-1292 RS73576045/0.01 3’ mir (mix) 3 2 1 0.00016146
CEU 4:115577997 C/G hsa-mir-577 RS34115976/0.12 3’ mir (mix) 22 17 5 0.048957519
7:129414574 A/G hsa-mir-96 RS41274239/0 Loop 1 0 1 <10-15
17:28444183 A/C hsa-mir-423 RS6505162/0.51 3’ mir 64 57 7 0.000893732
22:23165340 C/G hsa-mir-650 RS5996397/0.15 3’ mir (mix) 22 15 7 0.001677244
CHB 8:145625538 C/G hsa-mir-1234 RS141140965/0.38 5’ mir (mix) 83 66 17 0.000639166
17:28444183 A/C hsa-mir-423 RS6505162/0.51 3’ mir 91 20 71 0.030681656
20:58883605 T/G hsa-mir-646/hsa-miR-
646
RS6513497/0.19 3’ rom miR 36 36 0 0.049947315
CHS 7:129410227 C/T hsa-mir-182 RS76481776/0.05 3’ mir 3 2 1 9.68 × 10-07
8:145625538 C/G hsa-mir-1234 RS141140965/0.38 5’ mir (mix) 84 71 13 4.85 × 10-05
CLM 1:19223639 G/A hsa-mir-1290 RS75705742/0.01 5’ mir (mix) 1 0 1 9.44 × 10-15
2:180725568 T/C hsa-mir-1258 RS146754630/0.01 3’ mir 2 1 1 3.44 × 10-07
5:36148057 T/C hsa-mir-580 RS115089112/0.01 5’ mir (mix) 2 1 1 3.44 × 10-07
FIN 8:113655752 T/C hsa-mir-2053 RS10505168/0.37 5’ mir (mix) 57 51 6 0.047377863
18:33484792 G/A hsa-mir-187 RS41274312/0.01 3’ mir 3 2 1 2.41 × 10-06
GBR 12:95228286 G/C hsa-mir-492 RS2289030/0.12 3’ mir (mix) 8 6 2 0.01260062
14:100774203 C/T hsa-mir-345 RS72631832/0.01 5’ mir 7 5 2 0.004139358
IBS 20:58883534 T/C hsa-mir-646 RS6513496/0.24 5’ mir (mix) 3 1 2 0.039045114
22:23165340 C/G hsa-mir-650 RS5996397/0.15 3’ mir (mix) 3 1 2 0.039045114
JPT 2:47604866 C/T hsa-mir-559 RS58450758/0.2 3’ mir (mix) 31 23 8 0.039987277
10:53059406 T/C hsa-mir-605 RS2043556/0.28 3’ mir (mix) 39 27 12 0.025845926
19:54240174 G/A hsa-miR-516b-3p RS78861479/0.02 3’ rom miR 13 8 5 2.23 × 10-05
LWK 8:145625538 C/G hsa-mir-1234 RS141140965/0.38 5’ mir (mix) 59 53 6 0.040183314
14:101522556 T/C hsa-mir-323b RS56103835/0.3 5’ mir 3 2 1 1.43 × 10-06
20:62551199 T/C hsa-mir-941-4;hsa-mir-
941-3
RS7360929/0.09 5’ mir (mix) 15 12 3 0.039190789
20:62574006 A/G hsa-mir-647 RS73147065/0.23 3’ mir (mix) 64 36 28 0.017952613
MXL 12:104324266 G/A hsa-mir-3652 RS17797090/0.06 3’ mir (mix) 3 2 1 8.32 × 10-05
PUR 2:241395500 A/G hsa-mir-149 RS71428439/0.14 3’ mir 19 13 6 0.034768421
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Table 4 Variant positions with significant deviations from Hardy-Weinberg equilibrium (Continued)
7:158325503 C/T hsa-mir-595 RS4909237/0.18 5’ mir (mix) 19 12 7 0.008555965
10:14478618 T/C hsa-mir-1265 RS11259096/0.09 3’ mir (mix) 3 1 2 1.18 × 10-05
TSI 5:179225324 G/A hsa-mir-1229 RS2291418/0.03 5’ mir (mix) 4 2 2 1.25 × 10-06
8:145625538 C/G hsa-mir-1234 RS141140965/0.38 5’ mir (mix) 54 51 3 0.016552142
YRI 2:47604866 C/T hsa-mir-559 RS58450758/0.2 3’ mir (mix) 60 54 6 0.006410575
8:145625538 C/G hsa-mir-1234 RS141140965/0.38 5’ mir (mix) 52 48 4 0.026373978
Population, the population where the SNV was found; Location Chr:position, the location (chromosome:position, according to the human genome build GRCh37, hg19) of the SNV; SNV, the change observed
(reference allele/alternative allele); Pre-mir/mature, the identifier of the pre-mir and the mature miRNA when the SNV affects it; [dbSNP]/[1000g aaf], identifiers in dbSNP and/or 1000 Genomes when already
described; Region, the region in which the SNV maps within the miRNA structure (Figure 1, bottom); Number of subjects, the number of individuals supporting the SNV; Number of heterozygous, the number of
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Figure 5 Relationships between miRNAs, diseases in which they are involved and populations. Heat maps were produced using an
agglomerative clustering algorithm with Euclidean distances. (a) Heat map portraying the similarity between populations in terms of shared variants at
each position of the miRNA precursor compared. The color code represents the number of common variants between population pairs. (b) Heat map of
similarity between populations when only those positions mapping in the seed regions of the miRNAs are considered in the comparison. The color code
represents the number of common variants between population pairs with the analysis restricted to variants mapping in the seed regions. (c) Heat map
of the distribution of diseases across populations. The color code represents the number of variants per population associated with each disease
category. (d) Hive plot showing the relationships between miRNAs, populations and diseases, with the diseases summarized in general categories.
Carbonell et al. Genome Medicine 2012, 4:62
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Figure 6 Relationships between miRNAs, pathway categories and populations. (a) Heat map of the distribution of pathway categories
across populations. Color code represents the percentage of pathways potentially altered within any of the categories. A pathway is considered
to be affected if one of its genes is targeted by any miRNA with variants in the seed region. (d) Hive plot showing the relationships between
miRNAs, populations and pathway categories.
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Additional material
Additional file 1: Variant positions found. Excel file containing a
comprehensive list of the 527 variant positions found in the study.
Additional file 2: Diseases in which miRNAs with variant positions
have been involved. Excel file containing a comprehensive list of
diseases in which miRNAs with their seed regions affected by SNVs have
been involved, according to the human microRNA disease database.
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